Accelerate drug discovery and improve the diagnosis of disease through the digitization of chemically cleared biological tissues in 3D, coupled with automated image analysis and machine learning.

How did we start?

The inspiration for Visikol grew out of a plant microscopy class at Rutgers University in the fall of 2011. Visikol Chief Scientific Officer, Tom Villani, learned of the labor intensive process of obtaining and using the traditional plant clearing agent, chloral hydrate. As a highly regulated narcotic with a long history of abuse, chloral hydrate was far from an easily accessible or safe agent to use in biology research. Tom knew there had to be an easier way.

Working with an advisory team of Dr. Jim Simon and Dr. Adolfina Koroch, Visikol® was born in the labs at Rutgers University as a safe and easy-to-use clearing agent for plant biology research. As we very quickly learned, the potential of Visikol was not solely limited to plant biology. By working with Visikol we found new and unique ways to apply it to clear a wide range of biological tissues. We have since expanded beyond the world of plant biology, and are excited to bring you a suite of tissue clearing reagents as well as bio-imaging services. 

Visikol Team

Dr. Michael Johnson, Chief Executive Officer 

Dr. Johnson leads the day-to-day development of Visikol Inc, as well as the overall marketing/sales strategy for the Visikol technology platforms. 

Nick Crider, Chief Operating Officer     

Nick is responsible for both overall strategic and day-to-day operations of the company. Nick oversees the regulatory and legal concerns for Visikol.  

Dr. Thomas Villani Headshot - Visikol
Dr. Graeme Gardner Visikol Headshot
Erin Edwards Visikol

Dr. Tom Villani, Chief Science Officer
Dr. Villani is responsible for coupling R&D to business strategy at Visikol. Tom leads scientific research, product development, and academic collaborations for Visikol.


Dr. Graeme Gardner, Director of Research
Dr. Gardner is focused on applying the Visikol HISTO technology to high-value applications in the drug discovery space. Graeme leads the day-to-day operation of the lab and the development of various Visikol HISTO technology applications.


Dr. Erin Edwards, Director of In Vitro Studies
Dr. Edwards leads Visikol's 3D and 2D in vitro assay services and is responsible for developing best-in-class assays that leverage Visikol's 3Screen image analysis algorithms and high content confocal imaging.

Alex Magsam Headshot
Dr. Adam Kuehn - Visikol - Headshot

Alex Magsam, Imaging Scientist
Alex is focused on developing best-in-class 3D imaging and analysis algorithms for Visikol's 3Screen services. Additionally, Alex has led the development of Visikol's Clara optical CT scanner. 


Dr Adam Kuehn, Pathologist
Dr. Kuehn is a fellowship trained anatomical pathologist that leads Visikol's traditional histopathology services associated with its digital pathology portfolio of services.